Cilostazol and Endothelial Progenitor Cell

• Status: Active, not recruiting
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gyeongsang National University Hospital
• Collaborator: Korea Otsuka Pharmaceutical Co., Ltd.
• Treatments: Aspirin; Cilostazol; Clopidogrel

Criteria

Inclusion Criteria:

• naïve AMI

• undergoing successful coronary stent implantation

Exclusion Criteria:

• high-risk patients for thrombotic event;

• a history of active bleeding or bleeding diatheses;

• contraindication to antiplatelet therapy;

• hemodynamic or electrical instability;

• oral anticoagulation therapy;

• left ventricular ejection fraction < 30%;

• leukocyte count < 3,000/mm3 and/or platelet count < 100,000/mm3;

• AST or ALT > 3 times the respective the upper limit;

• serum creatinine level > 3.5 mg/dL;

• stroke within 3 months;

• pregnancy;

• non-cardiac disease with a life expectancy < 1 year;

• any patients not tolerable or suitable for coronary intervention; and

• inability to follow the protocol